Drug Trial Radar · NCT07227025
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 3, 2026
Primary completion
Nov 30, 2028
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose \[RP2CD\]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic non-small cell lung cancer (NSCLC: the most common type of lung cancer; metastatic: has spread to other parts of the body; KRAS G12C mutant: mutation \[change\] in the kirsten rat sarcoma viral oncogene homolog \[KRAS\] gene in tumor cells in which glycine \[G\] at position 12 is replaced with cystine \[C\]).
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
AmivantamabDrug
Amivantamab will be administered.
OlomorasibDrug
Olomorasib will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to approximately 3 years 2 months
- Phase 1: Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 3 years 2 months
- Phase 2: Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 3 years 2 months
Locations
12 sites in 5 countries. Site status is shown where the registry gives one.
New York University Langone Medical Center
New York, New York · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Princess Margaret Hospital
Toronto, Ontario, Canada · Recruiting
The First Affiliated Hospital Sun Yat sen University
Guangzhou, China · Recruiting
Harbin medical university cancer hospital
Harbin, China · Recruiting
Shanghai East Hospital
Shanghai, China · Recruiting
Severance Hospital Yonsei University Health System
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi
Ankara, Turkey (Türkiye) · Recruiting
Ankara Bilkent Sehir Hastanesi
Çankaya, Turkey (Türkiye) · Recruiting
Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi
Istanbul, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.